Last $114.77 USD
Change Today -1.22 / -1.05%
Volume 336.3K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Pacira Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $61.793 million compared to $33.564 million a year ago. Income from operations was $7.920 million compared to loss from operations of $9.820 million a year ago. Income before income taxes was $5.975 million compared to loss before income taxes of $11.956 million a year ago. Net income was $5.802 million or $0.14 per diluted common share compared to net loss of $11.956 million or $0.36 per basic and diluted common share a year ago. Non-GAAP net income was $14.460 million or $0.35 per basic common share compared to non-GAAP net loss of $7.635 million or $0.23 per basic and diluted common share a year ago. The company announced that as a measure of operating cash flow, it has generated adjusted EBITDA of $18.2 million. Overall cash accumulation in the quarter was offset by $7 million of capital expenditure. For the year, the company reported total revenues of $197.668 million compared to $85.551 million a year ago. Loss from operations was $5.165 million compared to $53.289 million a year ago. Loss before income taxes was $13.543 million compared to $64.351 million a year ago. Net loss was $13.716 million or $0.39 per basic and diluted common share compared to $63.909 million or $1.93 per basic and diluted common share a year ago. Non-GAAP net income was $15.245 million or $0.37 per diluted common share compared to non-GAAP net loss of $45.039 million or $1.36 per basic and diluted common share a year ago. For the year 2015, the company expects EXPAREL revenues of $310 million to $330 million, with approximately 10% of these projected revenues coming from the pending nerve block indication. The company announced that it expects to report excluding stock-based compensation so on a non-GAAP basis, product gross margin of 72% to 75%, R&D expense of $25 million to $30 million. The company expects to be generating substantial EBITDA in 2015. The company expects to incur $35 million of capital expenditure related to manufacturing capacity expansion development along with about $15 million of routine capital expenditure, so these investments will moderate its cash balance accumulation in 2015 from the starting point of $183 million. The company expects its cash taxes to be minimal in 2015 due to the initial application of an NOL balance of approximately $330 million.

Pacira Pharmaceuticals, Inc. to Report Q4, 2014 Results on Feb 24, 2015

Pacira Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Feb 24, 2015

Pacira Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 24, 2015

Pacira Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 24, 2015

Pacira Pharmaceuticals, Inc. - Analyst/Investor Day

To provide an overview of the company's future expansion plans for additional EXPAREL indications, as well as the leading DepoFoam-based product candidates

Pacira Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full-Year of 2014

Pacira Pharmaceuticals, Inc. provided revenue guidance for the fourth quarter and full-year of 2014. For the fourth quarter, the company expects total revenues of $61.8 million in the fourth quarter of 2014, which represents an increase of 84% over $33.6 million in the fourth quarter of 2013. For the full year 2014, the company expects total revenues of $197.7 million in 2014, a 13% increase over $85.6 million in 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $114.77 USD -1.22

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $53.81 USD +0.34
Cumberland Pharmaceuticals Inc $6.13 USD +0.24
Durect Corp $1.05 USD -0.02
Halyard Health Inc $46.04 USD -0.77
Teleflex Inc $121.69 USD +0.47
View Industry Companies
 

Industry Analysis

PCRX

Industry Average

Valuation PCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.9x
Price/Book 24.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.